JP2007530431A - 膵臓癌を治療するための組成物および方法 - Google Patents
膵臓癌を治療するための組成物および方法 Download PDFInfo
- Publication number
- JP2007530431A JP2007530431A JP2006525966A JP2006525966A JP2007530431A JP 2007530431 A JP2007530431 A JP 2007530431A JP 2006525966 A JP2006525966 A JP 2006525966A JP 2006525966 A JP2006525966 A JP 2006525966A JP 2007530431 A JP2007530431 A JP 2007530431A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- sirna
- cdh3
- pcdh1
- gpr107
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 16
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 15
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 14
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 14
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 131
- 101001070474 Homo sapiens Protein GPR107 Proteins 0.000 claims abstract description 100
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 claims abstract description 92
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 claims abstract description 92
- 101000601855 Homo sapiens Protocadherin-1 Proteins 0.000 claims abstract description 88
- 102100037551 Protocadherin-1 Human genes 0.000 claims abstract description 88
- 102100034143 Protein GPR107 Human genes 0.000 claims abstract description 80
- 230000014509 gene expression Effects 0.000 claims abstract description 59
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims abstract description 56
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 41
- 239000013598 vector Substances 0.000 claims abstract description 22
- 102100024153 Cadherin-15 Human genes 0.000 claims abstract 5
- 239000004055 small Interfering RNA Substances 0.000 claims description 120
- 239000002773 nucleotide Substances 0.000 claims description 66
- 125000003729 nucleotide group Chemical group 0.000 claims description 64
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 230000000692 anti-sense effect Effects 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 230000000295 complement effect Effects 0.000 claims description 21
- 238000001890 transfection Methods 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 108091028664 Ribonucleotide Proteins 0.000 claims description 16
- 239000002336 ribonucleotide Substances 0.000 claims description 16
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 16
- 108091034117 Oligonucleotide Proteins 0.000 claims description 15
- 101150074805 PCDH1 gene Proteins 0.000 claims description 15
- 108091081021 Sense strand Proteins 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 99
- 206010028980 Neoplasm Diseases 0.000 abstract description 24
- 201000011510 cancer Diseases 0.000 abstract description 19
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 230000010261 cell growth Effects 0.000 abstract description 8
- 210000004881 tumor cell Anatomy 0.000 abstract description 6
- 102100036360 Cadherin-3 Human genes 0.000 description 87
- 108020004999 messenger RNA Proteins 0.000 description 30
- 229920002477 rna polymer Polymers 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 101150059702 cdh-3 gene Proteins 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 238000003197 gene knockdown Methods 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 14
- 230000004663 cell proliferation Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 102000000905 Cadherin Human genes 0.000 description 11
- 108050007957 Cadherin Proteins 0.000 description 11
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 11
- 230000009368 gene silencing by RNA Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000000134 MTT assay Methods 0.000 description 8
- 231100000002 MTT assay Toxicity 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 8
- 238000000636 Northern blotting Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000010293 colony formation assay Methods 0.000 description 7
- 238000002493 microarray Methods 0.000 description 7
- 229920001184 polypeptide Chemical group 0.000 description 7
- 108090000765 processed proteins & peptides Chemical group 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 108700040559 Protocadherins Proteins 0.000 description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
- 108020004688 Small Nuclear RNA Proteins 0.000 description 5
- 102000039471 Small Nuclear RNA Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000000277 pancreatic duct Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 108091023045 Untranslated Region Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 102000014450 RNA Polymerase III Human genes 0.000 description 3
- 108010078067 RNA Polymerase III Proteins 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 101150018082 U6 gene Proteins 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 238000001001 laser micro-dissection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 101000714552 Mus musculus Cadherin-3 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101710141467 Protocadherin-1 Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001150496 Tosapusia duplex Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 102000008373 cell-cell adhesion mediator activity proteins Human genes 0.000 description 1
- 108040002566 cell-cell adhesion mediator activity proteins Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000007459 endoscopic retrograde cholangiopancreatography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001036 exonucleolytic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 108091008880 orphan GPCRs Proteins 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55580904P | 2004-03-24 | 2004-03-24 | |
| PCT/JP2005/005619 WO2005090572A2 (en) | 2004-03-24 | 2005-03-18 | Compositions and methods for treating pancreatic cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007530431A true JP2007530431A (ja) | 2007-11-01 |
| JP2007530431A5 JP2007530431A5 (enExample) | 2008-02-14 |
Family
ID=34961863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525966A Withdrawn JP2007530431A (ja) | 2004-03-24 | 2005-03-18 | 膵臓癌を治療するための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1735442A2 (enExample) |
| JP (1) | JP2007530431A (enExample) |
| CN (1) | CN1977044A (enExample) |
| WO (1) | WO2005090572A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9017669B2 (en) | 2009-12-28 | 2015-04-28 | Oncotherapy Science, Inc. | Anti-CDH3 antibodies and uses thereof |
| JP2019511216A (ja) * | 2016-03-01 | 2019-04-25 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 優性網膜色素変性の治療のためのａａｖベクター |
| US12203074B2 (en) | 2018-06-01 | 2025-01-21 | University Of Florida Research Foundation, Incorporated | Compositions and methods for treatment of dominant retinitis pigmentosa |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200908998A (en) * | 2007-06-27 | 2009-03-01 | Oncotherapy Science Inc | Compositions and methods of treating cancer |
| CA2696591C (en) | 2007-08-20 | 2016-10-11 | Oncotherapy Science, Inc. | Cdh3 peptide and medicinal agent comprising the same |
| WO2010001585A1 (en) | 2008-06-30 | 2010-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| HRP20180293T1 (hr) | 2010-02-10 | 2018-03-23 | Fujifilm Ri Pharma Co., Ltd. | Anti-kadherin antitijelo obilježeno radioaktivnim metalom |
| CN101825799A (zh) * | 2010-05-26 | 2010-09-08 | 福州华映视讯有限公司 | 裸眼立体显示器的组立方法 |
| CN108064244B (zh) | 2014-11-14 | 2021-09-17 | 诺华股份有限公司 | 抗体药物缀合物 |
| CN108866058B (zh) * | 2018-07-12 | 2021-09-10 | 苏州吉玛基因股份有限公司 | 靶向KRAS的siRNA及其在制备胰腺癌治疗药物中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE |
-
2005
- 2005-03-18 JP JP2006525966A patent/JP2007530431A/ja not_active Withdrawn
- 2005-03-18 EP EP05721546A patent/EP1735442A2/en not_active Withdrawn
- 2005-03-18 CN CNA2005800166735A patent/CN1977044A/zh active Pending
- 2005-03-18 WO PCT/JP2005/005619 patent/WO2005090572A2/en not_active Ceased
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9017669B2 (en) | 2009-12-28 | 2015-04-28 | Oncotherapy Science, Inc. | Anti-CDH3 antibodies and uses thereof |
| JP2019511216A (ja) * | 2016-03-01 | 2019-04-25 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 優性網膜色素変性の治療のためのａａｖベクター |
| US11118185B2 (en) | 2016-03-01 | 2021-09-14 | University Of Florida Research Foundation, Incorporated | AAV vectors for treatment of dominant retinitis pigmentosa |
| JP2022185052A (ja) * | 2016-03-01 | 2022-12-13 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 優性網膜色素変性の治療のためのａａｖベクター |
| JP7272795B2 (ja) | 2016-03-01 | 2023-05-12 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 優性網膜色素変性の治療のためのａａｖベクター |
| JP2025016451A (ja) * | 2016-03-01 | 2025-02-04 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 優性網膜色素変性の治療のためのａａｖベクター |
| JP7642211B2 (ja) | 2016-03-01 | 2025-03-10 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 優性網膜色素変性の治療のためのａａｖベクター |
| US12203074B2 (en) | 2018-06-01 | 2025-01-21 | University Of Florida Research Foundation, Incorporated | Compositions and methods for treatment of dominant retinitis pigmentosa |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005090572A3 (en) | 2006-04-13 |
| CN1977044A (zh) | 2007-06-06 |
| EP1735442A2 (en) | 2006-12-27 |
| WO2005090572A2 (en) | 2005-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011078418A (ja) | 肺癌を治療するための組成物および方法 | |
| Zhang et al. | MicroRNA‐146a targets PRKCE to modulate papillary thyroid tumor development | |
| US20100086526A1 (en) | Nucleic acid constructs and methods for specific silencing of h19 | |
| CN101796184A (zh) | 治疗癌症的组合物及方法 | |
| JP2007530431A (ja) | 膵臓癌を治療するための組成物および方法 | |
| JP4467559B2 (ja) | 細胞増殖を阻害する組成物および方法 | |
| JP2006500916A (ja) | ｈｎＲＮＰＡ１およびＡ２核酸分子と関連がある新形成を治療するための方法および組成物 | |
| TW200538739A (en) | EphA4 as therapeutic target of PRC and PDACa | |
| US11319541B2 (en) | Anticancer therapeutic intervention | |
| Zhang et al. | RNA interference, A potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer | |
| KR102707587B1 (ko) | miR-4487를 유효성분으로 함유하는 항암제 민감성 증진용 조성물 | |
| US20110110896A1 (en) | Modulating levels of RNA-binding proteins for the treatment of breast cancer | |
| US20060003956A1 (en) | Materials and methods for the derepression of the E-cadherin promoter | |
| JP5263730B2 (ja) | ネコ伝染性腹膜炎ウイルス（ｆｉｐｖ）の予防及び治療剤 | |
| JP2013039036A (ja) | ＨＩＦ−２αの発現を抑制する核酸 | |
| WO2007020645A1 (en) | Gene silencing of protease activated receptor 1 (par1) | |
| KR100986465B1 (ko) | Ｏｉｐ５ 유전자의 신규한 용도 | |
| WO2021016061A2 (en) | Inhibitors of microrna 451a for treatment of endometriosis | |
| JP2004350607A (ja) | テロメレース阻害剤 | |
| Pu et al. | Suppression of EGFR Expression by Antisense RNA and RNAi | |
| TW201718854A (zh) | 供ｐ２１基因調控之ＲＮＡ干擾劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071218 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071218 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100528 |